Company identity
Company number 08484947
Company profile
UK company 08484947, incorporated on 12 April 2013.
Cellesce Growing and scale up of patient derived organoids
Cellesce Limited is a UK company with status Active founded in 2013 based in Wales.
Company number 08484947
Updated 07 Jul 2026 09:49
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
DS01 | Transaction MzUzNzgzODQ0MGFkaXF6a2N4
Published 12 Aug 2026 09:09
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
29 Apr 2021 to 29 Apr 2023
There is an urgent and unmet medical need to discover new cancer therapeutics that specifically target diseased cells and minimise adverse side-effects. One of the hurdles to be overcome in identifying new treatments is the availability of a lab-based test system that can accurately predict the efficacy of novel compounds for further clinical development....
1 Mar 2021 to 31 Aug 2023
To implement an advanced data analysis pipeline to identify key morphometric signatures from 3D images of screened organoids in drug trials and to classify organoid response for the assessment of therapeutic efficacy for application in the pharmaceutical industry.
1 Jan 2021 to 30 Sep 2021
Organoids are 3-dimensional (3D) clusters of stem cells that come together and emulate the microenvironment within individual organs, whether that be liver, kidney, heart, gut or other specific organs. Essentially, they can be viewed as miniature, simplified organs. They typically range in size from a few micrometers to five millimeters and there are pote...
1 Jun 2020 to 30 Nov 2020
no public description
1 Aug 2019 to 31 Dec 2022
To develop novel, real-time, cell ‘happiness’ assays to allow optimisation of the growth of patient samples in 3D mini organ-like cultures. These 'organoids' can be used in drug discovery and genetics research.
1 Jul 2018 to 31 Oct 2020
"There is an urgent and unmet medical need to discover and develop new disease-modifying breast cancer therapeutics that specifically target diseased cells and minimise adverse side-effects. One of the hurdles to be overcome in identifying new treatments is the availability of a test system that accurately predicts the efficacy of novel compounds for furt...
1 Sep 2014 to 29 Feb 2016
Organoid culture is a new technique that, unlike the use of cell lines, maintains tumour properties in the lab. Organoid cultures should improve the rate at which new drugs are discovered since they should lower the number of ineffective drugs that make their way through animal testing; this will directly lead to new, more effective drugs plus reductions ...